
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is), initially developed to treat hyperglycemia in type 2 diabetes, have shown significant benefits for heart failure (HF) patients. A large cardiovascular trial demonstrated that these drugs reduce HF outcomes instead of having a neutral effect. The positive effects extend to patients with HF and preserved or reduced ejection fraction, reducing HF hospitalizations by 28% and CV death or HF hospitalizations by 23%.
Like
Save
Share